Siddharth Mittal
#149Managing Director and CEO
48
Age
25y
Exp
12y
Tenure
5/10
Risk
🎓 B.Com · Symbiosis College of Arts and Commerce, Pune
📜 CA (Chartered Accountant), CPA · Institute of Chartered Accountants of India (ICAI), Colorado (USA)
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
6
Agre
4
Neur
Biocon
Healthcare · Large Cap
Mature Stable · Innovation-Led
About
Siddharth Mittal is the Managing Director and CEO of Biocon, a Large Cap company in the Healthcare sector with a market cap of ₹63K Cr. A Pragmatic leader with 25 years of experience, he is known for data-driven decision-making and partnership seeker strategy. His tenure is marked by a methodical approach to navigating complex regulatory pathways for biosimilars and integrating large-scale acquisitions.
FAQ
What is Siddharth Mittal's leadership style?
Siddharth Mittal is classified as a Pragmatic leader. He is data-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Siddharth Mittal's educational background?
Siddharth Mittal holds a B.Com from Symbiosis College of Arts and Commerce, Pune and a CA (Chartered Accountant), CPA from Institute of Chartered Accountants of India (ICAI), Colorado (USA).
Who is the CEO of Biocon?
Siddharth Mittal is the Managing Director and CEO of Biocon. He has been with the company for 12 years and in the current role for 6 years.
Leadership DNA
ArchetypePragmatic
MotivationCategory Creator
CrisisSteady Hand
DecisionData-Driven
GrowthPartnership Seeker
PeopleNumbers Driven
InnovationDisruptor
PaceSteady-Marathon
PurposeMission-First
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationSector Adjacent
Leadership Evidence
“His tenure is marked by a methodical approach to navigating complex regulatory pathways for biosimilars and integrating large-scale acquisitions.”
⚡ Crisis●●●●○
Mittal maintained Biocon's operational focus and capital allocation consistency despite the significant regulatory scrutiny and USFDA inspections faced by the company.
🎯 Motivation●●●●○
He has focused on driving Biocon's leadership in the complex biosimilars space, transitioning the company from a research-led entity to a global player in affordable biologics.
👥 People●●●●○
As a former CFO, Mittal's leadership style is characterized by a rigorous, data-centric approach to operational efficiency and financial discipline across Biocon's business units.
📈 Growth●●●●●
Biocon's growth strategy under his leadership has relied heavily on strategic licensing and global collaborations, such as those with Viatris for biosimilars.
💡 Innovation●●●●○
Biocon pioneered the development of affordable biosimilars and complex generics, effectively creating new market categories for high-quality, cost-effective alternatives to expensive biologics.
🏃 Pace●●●●○
The biotechnology industry requires long, methodical R&D cycles and rigorous regulatory approvals, leading to a predictable, process-driven operational rhythm.
🌱 Purpose●●●●○
The company's core identity is built on the mission of democratizing global healthcare access, exemplified by its long-standing focus on making life-saving drugs affordable for patients in emerging markets.
🏷️ Brand●●●●●
The company is widely recognized for its deep scientific rigor and technical excellence in fermentation technology and complex molecule development.
🤝 Customer●●●●●
Biocon operates primarily as a global biopharmaceutical enterprise, supplying complex active pharmaceutical ingredients and finished biosimilar products to other pharmaceutical companies and healthcare institutions.
💼 Employer●●●○○
Biocon is highly regarded as a premier training ground for scientists and biotech professionals due to its advanced R&D facilities and complex regulatory exposure.
📋 Mandate
The company needs to pivot its complex biosimilars pipeline into high-margin global markets to combat commoditization in the generic segment.
🏢 Culture●●●●○
R&D-focused biotechnology entity that balances scientific innovation with global regulatory rigors, maintaining a culture of research-backed growth.
Financials
Revenue FY25₹15K Cr
PAT FY25₹1K Cr
Rev CAGR 5Y23.3%
OPM10.8%
NPM6.7%
ROE4.7%
ROCE3.7%
P/E78.8
Fwd P/E41.6
P/B1.8
D/E50
Promoter54.1%
Institutional28.8%
Mkt Cap₹63K Cr
Compensation
To Be Published
Data being verified from audited reports
